Literature DB >> 32349941

Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition.

Marta Araujo-Castro1, Marta Iturregui Guevara2, María Calatayud Gutiérrez3, Paola Parra Ramírez4, Paola Gracia Gimeno5, Felicia Alexandra Hanzu6, Cristina Lamas Oliveira7.   

Abstract

Initial evaluation of adrenal incidentalomas should be aimed at ruling out malignancy and functionality. For this, a detailed clinical history should be taken, and an adequate radiographic assessment and a complete blood chemistry and hormone study should be performed. The most controversial condition, because of the lack of consensus in its definition, is autonomous cortisol secretion. Our recommendation is that, except when cortisol levels <1.8μg/dL in the dexamethasone suppression test rule out diagnosis and levels ≥5μg/dL establish the presence of autonomous cortisol secretion, diagnosis should be based on a combined definition of dexamethasone suppression test ≥3μg/dL and at least one of the following: elevated urinary free cortisol, ACTH level <10 pg/mL, or elevated nocturnal cortisol (in serum and/or saliva). During follow-up, dexamethasone suppression test should be repeated, usually every year, on an individual basis depending on the results of prior tests and the presence of comorbidities potentially related to hypercortisolism. The initial radiographic test of choice for characterization of adrenal incidentalomas is a computed tomography scan without contrast, but there is no unanimous agreement on subsequent monitoring. Our general recommendation is a repeat imaging test 6-12 months after diagnosis (based on the radiographic characteristics of the lesion). If the lesion remains stable and there are no indeterminate characteristics, no additional radiographic studies would be needed. We think that patients with autonomous cortisol secretion with comorbidities potentially related to hypercortisolism, particularly if they are young and there is a poor control, may benefit from unilateral adrenalectomy. The indication for unilateral adrenalectomy is clear in patients with overt hormonal syndromes or suspected malignancy. In conclusion, adrenal incidentalomas require a comprehensive evaluation that takes into account the possible clinical signs and comorbidities related to hormonal syndromes or malignancy; a complete hormone profile (taking into account the conditions that may lead to falsely positive and negative results); and an adequate radiographic study. Monitoring and/or treatment will be decided based on the results of the initial evaluation.
Copyright © 2020 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adrenal incidentaloma; Adrenalectomy; Autonomous cortisol secretion; Dexamethasone suppression test; Incidentaloma adrenal; Secreción autónoma de cortisol; Suprarrenalectomía; Test de supresión con dexametasona

Year:  2020        PMID: 32349941     DOI: 10.1016/j.endinu.2020.03.002

Source DB:  PubMed          Journal:  Endocrinol Diabetes Nutr (Engl Ed)        ISSN: 2530-0180            Impact factor:   1.417


  6 in total

Review 1.  Adrenal ganglioneuroma: Prognostic factors (Review).

Authors:  Florica Sandru; Mihai Cristian Dumitrascu; Aida Petca; Mara Carsote; Razvan-Cosmin Petca; Ana Maria Oproiu; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-09-22       Impact factor: 2.751

Review 2.  Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review.

Authors:  Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals
Journal:  Endocrine       Date:  2020-11-21       Impact factor: 3.633

3.  Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion.

Authors:  Marta Araujo-Castro; Ana García Cano; Lucía Jiménez Mendiguchía; Héctor F Escobar-Morreale; Pablo Valderrábano
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

4.  Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.

Authors:  Marta Araujo-Castro; Paola Parra Ramírez; Cristina Robles Lázaro; Rogelio García Centeno; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Miguel Antonio Sampedro Núñez; Mónica Marazuela; Héctor F Escobar-Morreale; Pablo Valderrabano
Journal:  J Clin Med       Date:  2021-11-25       Impact factor: 4.241

5.  Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours.

Authors:  Marta Araujo-Castro; Rogelio García Centeno; Cristina Robles Lázaro; Paola Parra Ramírez; Paola Gracia Gimeno; Patricia Martín Rojas-Marcos; Mariana Tomé Fernández-Ladreda; Juan Carlos Percovich Hualpa; Miguel Sampedro Núñez; María-Carmen López-García; Cristina Lamas; Cristina Álvarez Escolá; María Calatayud Gutiérrez; Concepción Blanco Carrera; Paz de Miguel Novoa; Nuria Valdés Gallego; Felicia Hanzu; Mónica Marazuela; Mireia Mora Porta; César Mínguez Ojeda; Isabel García Gómez Muriel; Héctor F Escobar-Morreale; Pablo Valderrabano
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

Review 6.  Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.

Authors:  Marta Araujo-Castro; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.